Phio Pharmaceuticals (NASDAQ:PHIO) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Phio Pharmaceuticals (NASDAQ:PHIO) posted its quarterly earnings data on Sunday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02), MarketWatch Earnings reports.

PHIO stock opened at $2.22 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.33 and a quick ratio of 10.33. The stock has a market capitalization of $12.83 million, a P/E ratio of -0.21 and a beta of 2.33. The business has a 50-day moving average of $2.18 and a 200-day moving average of $2.33. Phio Pharmaceuticals has a fifty-two week low of $1.60 and a fifty-two week high of $13.69.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Phio Pharmaceuticals in a research report on Friday, August 14th.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body.

Featured Story: NASDAQ

Earnings History for Phio Pharmaceuticals (NASDAQ:PHIO)

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with's FREE daily email newsletter.